Clinical Trials : Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines.
Clinical Trials: Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines is a practical guidebook for those engaged in clinical trial design. This book details the organizations and content of clinical trials, including trial design, safety, endpoints, subgroups, HRQoL, conse...
Clasificación: | Libro Electrónico |
---|---|
Autor principal: | |
Formato: | Electrónico eBook |
Idioma: | Inglés |
Publicado: |
Burlington :
Elsevier Science,
2011.
|
Temas: | |
Acceso en línea: | Texto completo |
Tabla de Contenidos:
- Front Cover; Clinical Trials: Study Design, Endpoints and Biomarkers, Drug Safety, FDA and ICH Guidelines; Copyright Page; Contents; Acknowledgments; Preface; The Study Schema and Study Design; Intent to Treat Analysis; How to Choose the Endpoints; Diagnostic Tests; Mechanism of Action; Standards; Methodology; Clinicaltrials. Gov and other Registries for Clinical Trials; Introduction; Abbreviations and Definitions; Biography; 1 The Origins of Drugs; I. Introduction; II. Structures of Drugs; a. Origins of warfarin; b. Origins of methotrexate and 5-fluorouracil; c. Origins of ribavirin.
- D. Origins of paclitaxele. Origins of cladribine; f. Origins of drugs in high-throughput screening; g. Origins of therapeutic antibodies; III. The 20 Classical Amino Acids; IV. Animal Models; a. Introduction; b. Estimating human dose from animal studies; 1. NOAEL approach; 2. MABEL approach; c. Scaling up the drug dose, acquired from animal studies, for use in humans; 2 Introduction to Regulated Clinical Trials; I. Introduction; II. Study Design; III. The Study Schema; a. Examples of schema from clinical trials; b. Sequential treatment versus concurrent treatment
- the Perez schema.
- C. Neoadjuvant chemotherapy versus adjuvant chemotherapy
- the Gianni schemad. Neoadjuvant chemotherapy plus adjuvant chemotherapy
- the Untch schema; e. Forwards sequence and reverse sequence
- the Puhalla schema; f. Both arms received three drugs, each arm at a different schedule
- the Sekine schema; g. Staging
- the Blumenschein schema; h. Staging and restaging
- the Czito schema; i. Methodology tip
- staging; j. Decision tree
- the Baselga schema; k. Decision tree
- the Katsumata schema; l. Methodology tip
- what is "tumor progression"?
- M. Methodology tip
- unit of drug dose expressed in terms of body surface arean. Run-in period
- the schema of Dy; o. Methodology tip
- c-kit and imatinib; p. Run-in period
- the Hanna schema; q. How to maintain blinding of the treatment, when the study drug and the control treatment are provided by different-sized pills (or by different volumes of solutions) ... ; r. Methodology tip
- bevacizumab and VEGF; s. Dose escalation
- the Moore schema; t. Pharmacokinetics
- the Marshall schema; IV. Further Concepts In Study Design; a. Active control; b. Add-on design active control.
- C. Three-arm study
- clinical trial with two different active control armsV. Summary; VI. Amendments to the Clinical Study Protocol; 3 Run-In Period; I. Introduction; a. Washout period; b. Detecting baseline adverse events; c. Excluding potential study subjects who have safety issues correlating with the study drug; d. To include only study subjects with controllable pain; e. To determine the maximal tolerable dose; f. To achieve and ensure steady state in vivo concentrations of study drug.